Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Creative Medical Technology Holdings (CELZ) Gross Margin (2017 - 2025)

Creative Medical Technology Holdings (CELZ) has disclosed Gross Margin for 9 consecutive years, with 60.0% as the latest value for Q1 2025.

  • On a quarterly basis, Gross Margin changed N/A to 60.0% in Q1 2025 year-over-year; TTM through Sep 2025 was 60.0%, a 0.0% change, with the full-year FY2024 number at 60.0%, changed 0.0% from a year prior.
  • Gross Margin was 60.0% for Q1 2025 at Creative Medical Technology Holdings, roughly flat from 60.0% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 70.91% in Q3 2022 to a low of 41.78% in Q4 2021.
  • A 5-year average of 59.25% and a median of 60.0% in 2021 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: crashed -1714bps in 2021, then surged 2758bps in 2022.
  • Creative Medical Technology Holdings' Gross Margin stood at 41.78% in 2021, then surged by 66bps to 69.35% in 2022, then decreased by -13bps to 60.0% in 2023, then changed by 0bps to 60.0% in 2024, then changed by 0bps to 60.0% in 2025.
  • Per Business Quant, the three most recent readings for CELZ's Gross Margin are 60.0% (Q1 2025), 60.0% (Q4 2024), and 60.0% (Q2 2024).